Global Short Bowel Syndrome (SBS) Market to Reach US$6.4 Billion by 2030

The global market for Short Bowel Syndrome (SBS) estimated at US$2.0 Billion in the year 2024, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 21.6% over the analysis period 2024-2030. GLP-2, one of the segments analyzed in the report, is expected to record a 23.2% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Growth Hormone segment is estimated at 21.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$553.3 Million While China is Forecast to Grow at 20.1% CAGR

The Short Bowel Syndrome (SBS) market in the U.S. is estimated at US$553.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$934.2 Million by the year 2030 trailing a CAGR of 20.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.4% and 17.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global Short Bowel Syndrome (SBS) Market - Key Trends and Drivers Summarized

Why Is the Short Bowel Syndrome (SBS) Market Gaining Attention in the Healthcare Industry?
The Short Bowel Syndrome (SBS) market is gaining attention in the healthcare industry due to the rising incidence of gastrointestinal disorders and the increasing need for effective management of SBS, a condition characterized by inadequate nutrient absorption due to surgical removal of a significant portion of the small intestine. Patients with SBS face challenges such as malnutrition, dehydration, diarrhea, and dependence on parenteral nutrition (PN) or enteral nutrition (EN) support, making comprehensive management essential. The growing focus on improving patient outcomes, quality of life, and reducing long-term healthcare costs is driving the demand for innovative therapies, including pharmacological treatments, nutritional support, and surgical interventions, in the management of SBS.

How Are Technological Advancements and New Therapies Transforming the SBS Market?
Technological advancements and new therapies are significantly transforming the SBS market by enhancing the efficacy, safety, and convenience of SBS management. The development of novel pharmacological treatments, such as glucagon-like peptide-2 (GLP-2) agonists, growth hormones, and enzyme replacements, is improving intestinal adaptation, absorption, and fluid retention, reducing the need for parenteral nutrition and hospital visits. The emergence of personalized, multidisciplinary, and nutrition-based care models, supported by telemedicine, remote monitoring, and digital health platforms, is enabling more tailored and patient-centric approaches to SBS management. Additionally, advancements in regenerative medicine, gene therapy, and microbiome-based treatments are opening new frontiers in SBS research, offering the potential for long-term solutions and reduced complications.

Which Market Segments Are Leading the Adoption of SBS Therapies?
Treatment types include parenteral nutrition (PN), enteral nutrition (EN), pharmacological therapies, and surgical interventions, with PN and pharmacological therapies being the most widely adopted due to their critical role in providing essential nutrients, fluids, and managing symptoms. Patient types encompass pediatric, adult, and post-surgical SBS patients, with pediatric and post-surgical segments leading the market due to the high prevalence of congenital, post-surgical, and acquired SBS conditions. Distribution channels include hospitals, specialty clinics, retail pharmacies, and home healthcare, with hospitals and specialty clinics being the largest segments due to the need for specialized care, monitoring, and support. Asia-Pacific is emerging as a high-growth region driven by improving healthcare infrastructure and rising incidence of gastrointestinal disorders.

What Are the Key Drivers of Growth in the Short Bowel Syndrome (SBS) Market?
The growth in the Short Bowel Syndrome (SBS) market is driven by several factors, including the rising incidence of SBS and other gastrointestinal disorders, technological advancements in parenteral nutrition, enzymes, and pharmacological treatments, and the increasing use of human growth hormone, glucagon-like peptide-2 (GLP-2) agonists, and dietary supplements in SBS management. The development of orphan drugs, biologics, and novel surgical techniques with enhanced efficacy, safety, and convenience is driving market adoption among hospitals, specialty clinics, and home healthcare providers. The focus on enhancing multidisciplinary, patient-centric care models, self-management, and remote monitoring is expanding the market reach among pediatric, adult, and post-surgical patients. The growing use of SBS therapies in combination with regenerative medicine, digital health, and artificial intelligence, coupled with the demand for personalized and nutrition-based SBS care solutions, is creating new opportunities for market growth. Additionally, the increasing investments in R&D for gene therapy, stem cell therapy, and microbiome-based treatments are further supporting market expansion.